Negative / Null Result ReportOpen accessMedicine· cited by 11

Evaluation and Application of a PET Tracer in Preclinical and Phase 1 Studies to Determine the Brain Biodistribution of Minzasolmin (UCB0599)

Joël Mercier; Massimo Bani; Anny‐Odile Colson; Massimiliano Germani; Marianna Lalla; Christophe Plisson; Mickaël Huiban; Graham E. Searle · 2023 · Molecular Imaging and Biology

WASTE classifies this as Negative / Null Result Report · AI classification, approximate

The study found no significant effect — useful as a negative control or null benchmark for your own design.

Abstract

Abstract Purpose Minzasolmin (UCB0599) is an orally administered, small molecule inhibitor of ASYN misfolding in development as a potential disease-modifying therapy for Parkinson’s disease. Here we describe the preclinical development of a radiolabeled tracer and results from a phase 1 study using the tracer to investigate the brain distribution of minzasolmin. Procedures In the preclinical study, two radiolabeling positions were investigated on the S -enantiomer of minzasolmin (UCB2713): [ 11 C]methylamine UCB2713 ([ 11 C- N -CH 3 ]UCB2713) and [ 11 C]carbonyl UCB2713 ([ 11 C-CO]UCB2713). Ma

Abstract by Joël Mercier; Massimo Bani; Anny‐Odile Colson; Massimiliano Germani; Marianna Lalla; Christophe Plisson; Mickaël Huiban; Graham E. Searle, Molecular Imaging and Biology (2023) — licensed CC BY 4.0.

Read the full paper (open access)